Research into semaglutides safety profile during breastfeeding is still evolving
UK-based dispatch, strictly for preclinical and laboratory research
Smaller meals, slower eating, adequate fluids, and attention to protein can be helpful strategies for many patients

Researchers theorize this may be because: GIP activation may counterbalance some GLP-1 effects on the gut Dose escalation schedule allows more gradual adaptation Different pharmacokinetic profile may produce less pronounced peaks Serious Side Effects (Both Medications): These are rare but require immediate medical attention: Pancreatitis: Severe abdominal pain that may radiate to the back Risk: Less than 1% with both medications Usually occurs in first few months of treatment Requires immediate discontinuation if suspected Gallbladder Problems: Gallstones, cholecystitis (gallbladder inflammation) Symptoms: Right upper abdominal pain, nausea, fever More common with rapid weight loss May require surgical intervention Kidney Problems: Dehydration from vomiting/diarrhea can affect kidney function Watch for decreased urination, swelling in legs Stay well-hydrated, especially during side effect periods Thyroid Tumors (Black Box Warning): Both medications carry warnings about thyroid C-cell tumors Based on rodent studies

This ensures your safety and optimizes treatment outcomes
This titration schedule helps reduce gastrointestinal side effects, allowing your body time to adjust to each dose level